StockData
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp (UTHR) stock

UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$584.10−3.78 (-0.64%)

Close on Nov 17, 2026Market cap $25.05BP/E 20.9Yield –

United Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

United Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $551.50M, up 6.0% year over year. For fiscal 2025 it was $550.00M, up 14.3% from the year before. Over ten years it grew 8.4% a year on average. The highest annual figure on record is $1.18B in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$550.00M+14.3%
FY2024Dec 31, 2024$481.00M+17.9%
FY2023Dec 31, 2023$408.00M+26.4%
FY2022Dec 31, 2022$322.90M-40.2%
FY2021Dec 31, 2021$540.10M+51.0%
FY2020Dec 31, 2020$357.70M-69.8%
FY2019Dec 31, 2019$1.18B+230.4%
FY2018Dec 31, 2018$357.90M+35.3%
FY2017Dec 31, 2017$264.60M+79.3%
FY2016Dec 31, 2016$147.60M-39.8%
FY2015Dec 31, 2015$245.10M+1.1%
FY2014Dec 31, 2014$242.50M-19.0%
FY2013Dec 31, 2013$299.35M+72.6%
FY2012Dec 31, 2012$173.39M-3.7%
FY2011Dec 31, 2011$180.02M+8.9%
FY2010Dec 31, 2010$165.31M+37.3%
FY2009Dec 31, 2009$120.37M-49.7%
FY2008Dec 31, 2008$239.18M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$146.30M+9.2%
Q1 FY2026Mar 31, 2026$138.20M-7.2%
Q4 FY2025Dec 31, 2025$139.50M+4.3%
Q3 FY2025Sep 30, 2025$127.50M+23.2%
Q2 FY2025Jun 30, 2025$134.00M-4.0%
Q1 FY2025Mar 31, 2025$149.00M+43.1%
Q4 FY2024Dec 31, 2024$133.80M-11.6%
Q3 FY2024Sep 30, 2024$103.50M+22.2%
Q2 FY2024Jun 30, 2024$139.60M+56.9%
Q1 FY2024Mar 31, 2024$104.10M+25.6%
Q4 FY2023Dec 31, 2023$151.40M+61.2%
Q3 FY2023Sep 30, 2023$84.70M+28.1%
Q2 FY2023Jun 30, 2023$89.00M-5.2%
Q1 FY2023Mar 31, 2023$82.90M+20.1%
Q4 FY2022Dec 31, 2022$93.90M+13.3%
Q3 FY2022Sep 30, 2022$66.10M-16.5%
Q2 FY2022Jun 30, 2022$93.90M+26.4%
Q1 FY2022Mar 31, 2022$69.00M-77.3%
Q4 FY2021Dec 31, 2021$82.90M-34.3%
Q3 FY2021Sep 30, 2021$79.20M+15.3%
Q2 FY2021Jun 30, 2021$74.30M-17.2%
Q1 FY2021Mar 31, 2021$303.70M+314.9%
Q4 FY2020Dec 31, 2020$126.10M+11.0%
Q3 FY2020Sep 30, 2020$68.70M-19.8%
Q2 FY2020Jun 30, 2020$89.70M+4.4%
Q1 FY2020Mar 31, 2020$73.20M-91.8%
Q4 FY2019Dec 31, 2019$113.60M-18.2%
Q3 FY2019Sep 30, 2019$85.70M-15.2%
Q2 FY2019Jun 30, 2019$85.90M+4.4%
Q1 FY2019Mar 31, 2019$897.40M+2413.7%
Q4 FY2018Dec 31, 2018$138.80M+107.5%
Q3 FY2018Sep 30, 2018$101.10M+120.3%
Q2 FY2018Jun 30, 2018$82.30M–
Q1 FY2018Mar 31, 2018$35.70M–
Q4 FY2016Dec 31, 2016$66.90M–
Q3 FY2016Sep 30, 2016$45.90M–

More United Therapeutics figures

See a number that looks wrong?